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Background: The infused cell dose is an important deter-
minant of engraftment after CB transplantation. Thus, cell
loses during manufacturing and samples for testing must be
minimized. The AutoXpress (AXP) system is used for pro-
cessing of HPC-CB FDA licensed products in our Bank. With
this, collected CB is separated into three components (frac-
tions): red blood cells (RBC), plasma (P) and mononuclear
cells (MNC), which represent the ﬁnal HPC-CB product.
Methods: To optimize the number of HPC-CB cells to be
cryopreserved, we explored the suitability of RBC or P
samples as surrogates of the ﬁnal product for testing of
bacteria/fungi contamination. We evaluated the distribution
of 7 microorganisms, spiked into whole CB collections at
known concentrations (triplicate studies for each microor-
ganism), into each of the three post-processing fractions.
Further, a Rapid Microbiological Method (VersaTREK, Ther-
moFisher Scientiﬁc, OH) was used for the detection of
bacteria/fungi in samples of RBC, MNC and P and compared
to the gold standard bacteriology method (USP<71>).
Results: Spiked microorganisms were distributed differ-
ently: Pseudomonas aeruginosa, Enterococcus faecalis, Staph-
ylococcus epidermidis, Propionibacterium acnes (Pac) and
Bacillus subtiliswere concentrated preferentially in the MNC,
while Candida albicans and Aspergillus Niger were more so in
the RBC fraction. Nonetheless, the VersaTREK detected all
microorganisms (sensitivity 100 CFU/ bottle) from all three
fractions with a comparable time to detection (TTD) for RBC
and MNC samples (all  14 days). A 10-fold higher P volume
(5 mL) was used to detect growth at a TTD comparable to
MNC or RBC samples. Further, delayed detection, due to
partial inhibition of the growth of Pac, was seen with the
higher P volume.
Summary: The VersaTREK/Redox detects microorganisms
with sensitivity comparable to the standard method in all
three fractions after AXP-processing. Use of MNC or RBC did
not impact signiﬁcantly the ability or time to detection. The
use of samples from the RBC or P fractions, or possibly,
a combination of both for sterility screening of HPC-CB
products will preserve approx. 5% of the ﬁnal product
volume for transplant use.
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Background: After hematopoietic cell transplantation (HCT),
the risk of acute graft-vs.-host disease (GVHD) is increased in
male recipients of female grafts. Disparities for the male-
associated H-Y and other minor histocompatibility antigens
(mHAs) have the capacity to sensitize alloreactive donor T
cells and cause GVHD in HLA-matched recipients. We asked
whether regulatory T cells (Treg) exist speciﬁc for human
mHA.
Methods and Results: Tregs from normal donors were iso-
lated by CD25 immunoabsorption and cultured with
dendritic cells (DC) from HLA-matched siblings in the pres-
ence of IL-2, IL-15 and rapamycin. We detected a 15-fold
increase in 3H-TdR uptake at 6 days in Treg cultures stimu-
lated by HLA-identical, mHA incompatible sibling DC
compared to self-DC. The median precursor frequency of
mHA-speciﬁc Treg is 1.3 (range, 0.1-13.5) cells per million
total blood CD4 T cells, while the median frequency of mHA-
speciﬁc conventional CD4 (Tconv) is 25 (range, 3-141) per
million total blood CD4 T cells. Among 13 HLA-identical
sibling pair tested in any gender combination, there was a 26
(range, 8 to 39)-fold excess mHA-speciﬁc Tconv over mHA-
speciﬁc Treg in the donor blood. It is the predominance of
alloreactive Tconv over Tregs that drives the immune
response causing GVHD. Puriﬁed Tregs were expanded in
culturewith for 12 days with DC from aHLA-identical sibling,
IL-2, IL-15 and rapamycin (n¼5), and the frequency of mHA-
speciﬁc Tregs expanded 147 to 394-folds. Tregs responded to
re-stimulation with DC from the original HLA-identical
sibling, but not self-DC. The mHA-speciﬁc Tregs exhibited
antigen speciﬁc suppression. When Tregs were cultured at
limiting dilution, we obtained 4 mHA-speciﬁc Treg clones
that retained TGFb secretion in response to the sibling's
mHA-disparate DC but not self-DC. One of these clones from
a female donor responded to HY-antigen DBY expressed on
self-APC after gene transduction and not UTY or DC alone,
while another clone responded to UTY not DBY or self-DC
alone. We adapted our protocol to GMP-compatible, large
scale expansion of Treg from apheresis of 3.7 x 1010cells.
Cultured Tregs maintained high levels of Foxp3 expression
and demethylation of the Treg-speciﬁc Foxp3 gene promoter
of the end-culture. mHA-speciﬁc Tregs were enriched 324-
folds during the 12-day culture, indicating that we will be
able to produce enough cells to exceed the numbers of mHA-
speciﬁc CD4 Tconv (CD4 Tconv/Treg ratio, range 8-29) using
a leukapheresis. We could not detect alloreactive T cells in
this culture, besides TGFb-producing Tregs. The end-of-
culture Tregs produced allospeciﬁc suppression with an IC50
between 1:1,000 and 1:10,000.
Conclusions: We demonstrated for the ﬁrst time that it is
possible to detect and expand mHA speciﬁc Tregs from HLA-
matched sibling pairs. Immunotherapy with mHA-speciﬁc
Tregs against ubiquitous mHAs may prevent GVHD.163
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